The US biotech company Amgen reached an agreement to buy Horizon Therapeutics for more than 25 billion dollars. Horizon holds ...Read more
INVESTOR TIMES is an independent publication of economic, finance and investment content, owned and operated by Altas Ventures.
© ATLAS VENTURES SLU, all rights reserved. Any information contained in INVESTOR TIMES is for educational and/or informational purposes only, it is not financial and/or investment advice. INVESTOR TIMES may obtain economic retribution by recommending services or products of third parties. INVESTOR TIMES does not accept, nor will it accept in the future, subsidies or funds from Governments, political parties or public institutions.